XCUR (Exicure) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


XCUR Exicure Inc XCUR
30 GF Score
Price $2.58
GF Value $0.54
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exicure Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Exicure's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

XCUR vs GRTX, AEON, ANEB: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Exicure's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exicure Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Exicure's Margin of Safety % (DCF FCF Based) falls into.


XCUR
30GF Score
Exicure Inc XCUR
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exicure (XCUR) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of $2.58 is trading 377.8% above its estimated GF Value™ of $0.54. GuruFocus considers Exicure to be Significantly Overvalued.

Key valuation signals for XCUR:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $0.54 vs. price of $2.58 (377.8% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the XCUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exicure Business Description

Other Exchanges 2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
30GF Score

Get the complete analysis for XCUR

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.58
Price
$0.54
GF Value